Publication Highlights

Publication highlights

  • Urak R, Walter M, Lim L, Wong CW, Budde LE, Thomas S, et al. Ex vivo Akt inhibition promotes the generation of potent CD19CAR T cells for adoptive immunotherapy. Journal for Immunotherapy of Cancer. 2017;5:26. PubMed PMID: 28331616. Pubmed Central PMCID: PMC5359873. Epub 2017/03/24. eng.
  • Rosenzweig M, Urak R, Walter M, Lim L, Sanchez JF, Krishnan A, et al. Preclinical data support leveraging CS1 chimeric antigen receptor T-cell therapy for systemic light chain amyloidosis. Cytotherapy. 2017 Jul;19(7):861-6. PubMed PMID: 28483281. Epub 2017/05/10. eng.
  • Wang X, Popplewell LL, Wagner JR, Naranjo A, Blanchard MS, Mott MR, et al. Phase 1 studies of central memory-derived CD19 CAR T-cell therapy following autologous HSCT in patients with B-cell NHL. Blood. 2016 Jun 16;127(24):2980-90. PubMed PMID: 27118452. Pubmed Central PMCID: PMC4911862. Epub 2016/04/28. eng.
  • Hong H, Brown CE, Ostberg JR, Priceman SJ, Chang WC, Weng L, et al. L1 Cell Adhesion Molecule-Specific Chimeric Antigen Receptor-Redirected Human T Cells Exhibit Specific and Efficient Antitumor Activity against Human Ovarian Cancer in Mice. PloS One. 2016;11(1):e0146885. PubMed PMID: 26761817. Pubmed Central PMCID: PMC4711972. Epub 2016/01/14. eng.
  • Brown CE, Alizadeh D, Starr R, Weng L, Wagner JR, Naranjo A, et al. Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy. The New England Journal of Medicine. 2016 Dec 29;375(26):2561-9. PubMed PMID: 28029927. Pubmed Central PMCID: PMC5390684. Epub 2016/12/29. eng.
  • Wang X, Wong CW, Urak R, Mardiros A, Budde LE, Chang WC, et al. CMVpp65 Vaccine Enhances the Antitumor Efficacy of Adoptively Transferred CD19-Redirected CMV-Specific T Cells. Clinical Cancer Research : an official journal of the American Association for Cancer Research. 2015 Jul 01;21(13):2993-3002. PubMed PMID: 25838392. Pubmed Central PMCID: PMC4489991. Epub 2015/04/04. eng.
  • Mardiros A, Forman SJ, Budde LE. T cells expressing CD123 chimeric antigen receptors for treatment of acute myeloid leukemia. Current Opinion in Hematology. 2015 Nov;22(6):484-8. PubMed PMID: 26457961. Pubmed Central PMCID: PMC4624420. Epub 2015/10/13. eng.
  • Jonnalagadda M, Mardiros A, Urak R, Wang X, Hoffman LJ, Bernanke A, et al. Chimeric antigen receptors with mutated IgG4 Fc spacer avoid fc receptor binding and improve T cell persistence and antitumor efficacy. Molecular Therapy : the journal of the American Society of Gene Therapy. 2015 Apr;23(4):757-68. PubMed PMID: 25366031. Pubmed Central PMCID: PMC4395772. Epub 2014/11/05. eng.
  • Mardiros A, Dos Santos C, McDonald T, Brown CE, Wang X, Budde LE, et al. T cells expressing CD123-specific chimeric antigen receptors exhibit specific cytolytic effector functions and antitumor effects against human acute myeloid leukemia. Blood. 2013 Oct 31;122(18):3138-48. PubMed PMID: 24030378. Pubmed Central PMCID: PMC3814731. Epub 2013/09/14. eng.